BSX
New target, same faith
Boston Scientific just got the classic Wall Street version of a pat on the back with a haircut. Stifel kept its Buy rating on BSX, but dialed the price target down from $90 to $85.
That matters because price targets are basically the market’s mood ring. The analyst is still saying, “I like the stock,” just with a little less swagger than before. And when you’re already trading near the bottom of your 52-week range, even a modest trim can keep the pressure on.
Earnings are the bigger thundercloud
The timing here is spicy: Boston Scientific is set to report earnings Wednesday before the open. So this isn’t just one analyst tinkering with the calculator — it’s the calm-before-the-cash-flow-calls setup.
Investors are watching a few things:
- EPS is expected at 79 cents, up from 75 cents a year ago
- Revenue is pegged at $5.18 billion, versus $4.66 billion last year
- The stock is still sitting well below key moving averages, which is Wall Street speak for “the chart still looks a little grumpy”
Why you should care
When a stock is already under technical pressure, earnings can act like a trampoline or a trapdoor. A solid report could give BSX a reason to bounce; a miss could make the downtrend even more stubborn.
Big picture: Stifel still likes the story, but it’s clearly not pretending this is a victory lap.